PIERIS Proteolab
Develops innovative protein-based therapies with strategic partnerships to improve clinical outcomes.
Launch date
Employees
Market cap
CAD30.0m
Enterprise valuation
(CAD6m) (Public information from Sep 2024)
Share price
$16.16 PIRS
Company register number HRB 221043 (München)
Hallbergmoos Bavaria (HQ)
Financials
Estimates*
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 26.5m | 42.1m | 26.7m | 28.6m | 23.5m | 29.1m | 6.0m |
| % growth | 15 % | 59 % | (37 %) | 7 % | (18 %) | 23 % | (79 %) |
| EBITDA | (27.5m) | (23.7m) | (28.9m) | (43.8m) | (32.1m) | - | - |
| % EBITDA margin | (104 %) | (56 %) | (108 %) | (153 %) | (136 %) | - | - |
| Profit | (24.3m) | (23.2m) | (33.8m) | (41.6m) | (30.3m) | - | - |
| % profit margin | (92 %) | (55 %) | (127 %) | (146 %) | (128 %) | - | - |
| R&D budget | 37.7m | 50.0m | 42.3m | 60.6m | 48.2m | - | - |
| R&D % of revenue | 143 % | 119 % | 159 % | 212 % | 205 % | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€12.0m | Series A | ||
$6.4m | Series B | ||
$38.7m | Series B | ||
| N/A | $1.3m | Grant | |
| N/A | N/A | IPO | |
$13.0m | Post IPO Equity | ||
* | N/A | Acquisition | |
| Total Funding | CAD81.2m | ||
Related Content
Recent News about PIERIS Proteolab
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.